#YAP1 #SDC1 #proteoglycan #KRAS #glycotime #cancer
Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers.
0
0
0
0
#YAP1 #SDC1 #proteoglycan #KRAS #glycotime #cancer
Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers.